Thermo Fisher Scientific Inc. has successfully secured $2,500,000,000 in new investment capital from investors. The company, recognized as the world leader in serving science with annual revenue of approximately $40 billion, announced this funding round as it continues to advance its mission to enable customers in making the world healthier, cleaner, and safer.
Thermo Fisher Scientific supports a diverse range of customers globally. Its operations span accelerating life sciences research, solving complex analytical challenges, increasing productivity in laboratories, and improving patient health through diagnostics or the development and manufacture of life-changing therapies. The company delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through industry-leading brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.
This substantial capital infusion underscores investor confidence in Thermo Fisher Scientific's robust market position and its critical role across the scientific and healthcare landscapes. The $2.5 billion secured will be strategically allocated to fuel the company's ambitious growth objectives. These plans include potential investments in research and development, capacity expansion, and the continuous enhancement of its comprehensive suite of products and services designed to meet evolving customer needs globally.
The funding positions Thermo Fisher Scientific to further accelerate its strategic initiatives and reinforces its capacity to deliver essential solutions to its global customer base. This capital will support the company's ongoing commitment to innovation and its leadership in providing critical tools and services that underpin scientific discovery and advancements in human health worldwide.
